OncoMatch/Clinical Trials/NCT06007690
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Is NCT06007690 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for choroidal melanoma.
Treatment: Bel-sar · Suprachoroidal Microinjector · Infrared Laser · Sham Infrared Laser · Sham Microinjector — The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Retina Consultants of Alabama · Birmingham, Alabama
- UCSD Shiley Eye Institute, Jacobs Retina Center · La Jolla, California
- Doris Stein Eye Research Center · Los Angeles, California
- Stanford University School of Medicine · Palo Alto, California
- Retinal Consultants Medical Group, Inc. · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06007690 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages